Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients (Q42550142)

2 November 2017

title

Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients (English)

1 reference

2 November 2017

0 references

1 reference

Lane HY

1

1 reference

2 November 2017

Hu OY

2

1 reference

2 November 2017

Jann MW

3

1 reference

2 November 2017

Deng HC

4

1 reference

2 November 2017

Lin HN

5

1 reference

2 November 2017

Chang WH

6

1 reference

2 November 2017

language of work or name

English

0 references

publication date

1 March 1997

1 reference

2 November 2017

1 reference

2 November 2017

volume

69

1 reference

2 November 2017

issue

2-3

1 reference

2 November 2017

page(s)

105-111

1 reference

A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia. With particular reference to drug resistance

2 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

Extrapyramidal reactions in Asians

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

Metabolites of haloperidol display preferential activity at sigma receptors compared to dopamine D-2 receptors

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

Dose-dependent reduced haloperidol/haloperidol ratios in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

Development of an ELISA to study the polymorphism of dextromethorphan oxidation in a french population

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

Pharmacokinetics of haloperidol

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis.

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

Determination of dextromethorphan metabolizer phenotype in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

Dextromethorphan O-demethylation polymorphism in Jordanians

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

High-performance liquid chromatography determination of dextromethorphan and dextrorphan for oxidation phenotyping by fluorescence and ultraviolet detection

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

Low frequency of dextromethorphan O-demethylation deficiency in a Chinese population

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

Polymorphism of dextromethorphan oxidation in a French population

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

Neuroleptic dosage for Asians

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

Dextromethorphan polymorphic hepatic oxidation (CYP2D6) in healthy black American adult subjects

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

Polymorphic debrisoquin hydroxylation in 757 Swedish subjects

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota*

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

Haloperidol blood levels and clinical effects

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6

1 reference

https://api.crossref.org/works/10.1016/S0165-1781(96)02999-X

7 January 2021

10.1016/S0165-1781(96)02999-X

Identifiers

DOI

1 reference

2 November 2017

1 reference